TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25946305

Group type: EXPERIMENTAL
Intervention: Light shoes (352 ± 18.4 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Heavy shoes (637 ± 17.7 g)
Number of subjects: 22
Study: 23911013

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5, 5, or 10 mg/day
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 808
Study: 23631622

Group type: EXPERIMENTAL
Intervention: Motive-Oriented Therapeutic Relationship (MOTR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psychiatric-Psychodynamic Treatment
Number of subjects: 20
Study: 20614193

Group type: EXPERIMENTAL
Intervention: Early complete lymph node dissection (early CLND)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Delayed complete lymph node dissection (delayed CLND)
Number of subjects: 357
Study: 17651533

Group type: EXPERIMENTAL
Intervention: Flavourless gum (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mint-flavoured strips (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavourless gum or mint-flavoured strips
Number of subjects: 0
Study: 17064498

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (urokinase or rt-PA) for massive and sub-massive PTE
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Anticoagulant agents (IV infusion of unfractioned heparin or subcutaneous low-molecular-weight heparin) for non-massive PTE
Number of subjects: 516
Study: 12948097

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0
Study: 11036119

Group type: COMPARATOR
Intervention: Troponin T levels <0.06 microg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: Troponin T levels 0.06 to 0.59 microg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: Troponin T levels ≥0.60 microg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: C-reactive protein levels <2 mg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: C-reactive protein levels 2 to 10 mg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: C-reactive protein levels >10 mg/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: Fibrinogen levels <3.4 g/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: Fibrinogen levels 3.4 to 3.9 g/L
Number of subjects: 917

Group type: COMPARATOR
Intervention: Fibrinogen levels ≥4.0 g/L
Number of subjects: 917
Study: 7661066

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment (800 mg/day for 2 weeks, then 400 mg/day thereafter)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic therapy)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 2748528

Group type: EXPERIMENTAL
Intervention: Adinazolam (10 to 60 mg daily, divided doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 862331

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of antidiuretic hormone at a low rate for 1 hr
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of antidiuretic hormone
Number of subjects: 10
Study: 27353245

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate (Ritalin® LA at a dose of 0.6 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Extended-release methylphenidate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26405006

Group type: EXPERIMENTAL
Intervention: Continuous (inhibitory) TBS over S1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Continuous TBS over PPC
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intermittent (excitatory) TBS over PPC
Number of subjects: 5

Group type: COMPARATOR
Intervention: rTMS applied over M1
Number of subjects: 5
Study: 24029478

Group type: EXPERIMENTAL
Intervention: Increased posterior tibial slope (>6.6 degrees) in ACL rupture group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased slope of tibial plateau
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased posterior slope
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no ACL rupture)
Number of subjects: 150
Study: 21145618

Group type: EXPERIMENTAL
Intervention: ABT‐874 (dosage not specified)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 (through the first 48 weeks)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ABT‐874 (during the open-label extension)
Number of subjects: 180
Study: 18940114

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 1 ml/kg with tramadol 1 mg/kg body weight
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 1 ml/kg body weight
Number of subjects: 60
Study: 16849064

Group type: EXPERIMENTAL
Intervention: Bite-wafer group (BWG) - performed immediate supervised mastication of the wafers for 10 minutes and bit on the wafers to prevent pain for the next 7 days.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Reduced-mastication group (RMG) - instructed not to masticate for 3 hours after placement of the fixed appliance and to avoid masticating hard food for 7 days.
Number of subjects: 84
Study: 14584858

Group type: EXPERIMENTAL
Intervention: Combination therapy using an expanded polytetrafluoroethylene (ePTFE) membrane and demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 43
Study: 11103236

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐1 alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐FU alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and 5‐fluorouracil
Number of subjects: 0
Study: 9058218

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone, 50 micrograms/kg loading dose over 20 minutes followed by 0.5 microgram/kg/min infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Open-label milrinone administered after initial failure to wean from bypass
Number of subjects: 32

Group type: COMPARATOR
Intervention: Milrinone and placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 32
Study: 8412049

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 6 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3760657

Group type: EXPERIMENTAL
Intervention: Culture medium containing no protein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Culture medium containing 10% maternal serum (Control)
Number of subjects: 100
Study: 31377895

Group type: EXPERIMENTAL
Intervention: Vaginal laser treatment (3 treatments administered 4 weeks apart)
Number of subjects: 26
Study: 29546832

Group type: EXPERIMENTAL
Intervention: TA‐65 (16 mg daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27121090

Group type: EXPERIMENTAL
Intervention: Living Life to the Full guided online CBT‐based life skills package with telephone or email support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed access to the Living Life to the Full guided online CBT‐based life skills package
Number of subjects: 0
Study: 24782291

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 34
Study: 22431716

Group type: EXPERIMENTAL
Intervention: Imiquimod, 5%, cream 5 d/wk for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Imiquimod, 5%, cream 5 d/wk for 3 months plus tazarotene, 0.1%, gel 2 d/wk for 3 months
Number of subjects: 90
Study: 20233193

Group type: EXPERIMENTAL
Intervention: Document modified using systematic improvement of lexicosyntactic readability
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Document modified by a working group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Unchanged document (control group)
Number of subjects: 159
Study: 18577931

Group type: EXPERIMENTAL
Intervention: Nifedipine in combination with haloperidol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Haloperidol only
Number of subjects: 51
Study: 15854633

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mug)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mug)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo oral
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo vaginal
Number of subjects: 160
Study: 11793395

Group type: EXPERIMENTAL
Intervention: Wa x UK vaccine (P1A[8],G6); single oral dose;
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wa x (DS-1 x UK) vaccine (P1A[8],G2); single oral dose;
Number of subjects: 0
Study: 10890259

Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg QD
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg BID
Number of subjects: 919

Group type: COMPARATOR
Intervention: Penicillin V 250 mg QID
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Cefdinir (both regimens)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 919

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 919
Study: 7580360

Group type: COMPARATOR
Intervention: Aprotinin (2 million KIU IV at induction of anesthesia and 2 million KIU added to the extracorporeal circuit, followed by infusion of 500 thousand KIU/h during surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epsilon-aminocaproic acid (10 g IV at induction of anesthesia, followed by infusion of 2 g/h for 5 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg IV within 30 minutes after induction of anesthesia, followed by infusion of 1 mg/kg per hour for 10 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no antifibrinolytic therapy)
Number of subjects: 60
Study: 1418152

Group type: EXPERIMENTAL
Intervention: Prophylactic catheter placement prior to selective embolization
Number of subjects: 9

Group type: COMPARATOR
Intervention: Emergent catheter placement for selective embolization
Number of subjects: 9
Study: 6370748

Group type: EXPERIMENTAL
Intervention: 0.1% Ro 12‐7024 ointment
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate ointment
Number of subjects: 39
Study: 31522546

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 332

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: nVNS (post hoc analysis)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Sham (post hoc analysis)
Number of subjects: 332
Study: 30084934

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 131
Study: 27213795

Group type: EXPERIMENTAL
Intervention: Gliatilin (1000 mg/4ml, 12-15 doses intravenously, then 1 capsule b.i.d. for 4 months orally)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard neuroprotective therapy (not specified)
Number of subjects: 240
Study: 24692481

Group type: EXPERIMENTAL
Intervention: Target systolic BP <150 mm Hg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Target systolic BP <180 mm Hg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Edematous region CBF
Number of subjects: 67

Group type: COMPARATOR
Intervention: Contralateral tissue CBF
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Systolic BP change
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Perihematoma relative CBF
Number of subjects: 67
Study: 22745199

Group type: EXPERIMENTAL
Intervention: ESWT at an energy level of 0.20 mJ/mm²
Number of subjects: 46

Group type: COMPARATOR
Intervention: ESWT at an energy level of 0.10 mJ/mm²
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 19672055

Group type: EXPERIMENTAL
Intervention: Structured written and oral information about asthma and asthma medication, and asthma diary
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 141
Study: 18576945

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (1.9, 3.8, 7.5, or 15 microg of hemagglutinin)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (higher doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (7.5 microg of hemagglutinin)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 200
Study: 16447664

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture with lifting manipulation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Scalp acupuncture with twirling manipulation
Number of subjects: 180
Study: 11989073

Group type: EXPERIMENTAL
Intervention: Intensive follow up (40 patients), controlled every 2 months with physical examination and lipid profile, diet and exercise enhancement, and statin dose adjustment.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (35 patients), evaluated once after 6 months.
Number of subjects: 75
Study: 10359885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: S-salbutamol 1.25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: R-salbutamol 1.25 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Racemic salbutamol 2.5 mg
Number of subjects: 11
Study: 7794578

Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 240 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 540 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 360 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem OD ER 240 mg and above
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1742382

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil (treated group)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 81
Study: 7000264

Group type: EXPERIMENTAL
Intervention: sulphinpyrazone 200 mg four times daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study: 30113933

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS-TA 4.0 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of CLS-TA 0.8 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 27862339

Group type: EXPERIMENTAL
Intervention: Cooling compound (CC) lotion applied twice daily for 4 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cooling compound (CC) lotion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 70
Study: 25714759

Group type: EXPERIMENTAL
Intervention: Urinary elimination of isofurans in the first 4 days after birth
Number of subjects: 254
Study: 22552590

Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Linseed oil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chlorhexidine (positive control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-rinsed control samples (negative control)
Number of subjects: 8
Study: 22561365

Group type: EXPERIMENTAL
Intervention: Adenovirus serotype 5 (Ad5)‐vectored HIV vaccine
Number of subjects: 1836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1836
Study: 21203519

Group type: EXPERIMENTAL
Intervention: Open-label placebo pills (inert substance, like sugar pills)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Open-label placebo pills
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 80
Study: 17425744

Group type: EXPERIMENTAL
Intervention: Group B (lower-C(2) range)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Group A (higher-C(2) range)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 141
Study: 16320346

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) plus elemental calcium (1,200 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Elemental calcium alone (control)
Number of subjects: 33
Study: 12856761

Group type: EXPERIMENTAL
Intervention: Object of My Affection (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Father of the Bride II (control group)
Number of subjects: 0
Study: 9690406

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Amoxycillin (n=197)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398) - Non-severe pneumonia
Number of subjects: 595

Group type: COMPARATOR
Intervention: Amoxycillin (n=197) - Non-severe pneumonia
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398) - Severe pneumonia
Number of subjects: 595

Group type: COMPARATOR
Intervention: Amoxycillin (n=197) - Severe pneumonia
Number of subjects: 595
Study: 7989461

Group type: EXPERIMENTAL
Intervention: Pamidronate (150 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3053570

Group type: EXPERIMENTAL
Intervention: Spiramycin 2 g orally daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Erythromycin 2 g orally daily
Number of subjects: 198
Study: 29027771

Group type: EXPERIMENTAL
Intervention: Continuous popliteal sciatic nerve block at the bifurcation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous popliteal sciatic nerve block proximal to the bifurcation
Number of subjects: 40
Study: 27622692

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (two injections at baseline and after 6 months, n=10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (n=10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (n=14)
Number of subjects: 24
Study: 25603897

Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-load traditional resistance training (low-load TRT)
Number of subjects: 10
Study: 23899063

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with doxorubicin and paclitaxel
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Residual Disease in Breast and Nodes (RDBN) classification
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lymph node metastases
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) scores
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Miller‐Payne grading and Sataloff tumor scores
Number of subjects: 62
Study: 20070351

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily (N = 528)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Metformin 1000 mg twice daily (N = 522)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1050
Study: 18760583

Group type: EXPERIMENTAL
Intervention: TIO 18 microg once-daily (8 am) + FOR 12 microg (8 pm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single-drug treatments
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tr4 (TIO 18 microg (8 am) + FOR 12 microg twice-daily (8 am and 8 pm))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tr5 (FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm))
Number of subjects: 80
Study: 16826474

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) treatment
Number of subjects: 1503
Study: 12673696

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens incorporating gemcitabine and paclitaxel with a platinum complex, with or without ifosfamide or doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate/vinblastine/doxorubicin/cisplatin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens predicated on taxanes and gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard single agents (methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study: 10502712

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8895622

Group type: EXPERIMENTAL
Intervention: Capsular closure with the knee in full extension
Number of subjects: 64

Group type: COMPARATOR
Intervention: Capsular closure with the knee in flexion
Number of subjects: 64
Study: 2049421

Group type: EXPERIMENTAL
Intervention: Initial 24 hours lavage before resumption of routine CAPD schedule
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continued prolonged exchanges as in routine CAPD schedule
Number of subjects: 36
Study: 6364688

Group type: EXPERIMENTAL
Intervention: i.m. injection of 15‐methyl PGF2 alpha, 0.25 mg every second hour
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide, 0.5 mg every fourth hour
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: laminaria tent
Number of subjects: 120

Group type: COMPARATOR
Intervention: 15‐methyl PGF2 alpha
Number of subjects: 120

Group type: COMPARATOR
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide
Number of subjects: 120
Study: 30312394

Group type: EXPERIMENTAL
Intervention: Soap-on-a-rope intervention in intervention schools
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 50
Study: 29378502

Group type: EXPERIMENTAL
Intervention: Facial anthropometric measurements using Digimizer version 4.1.1.0
Number of subjects: 50
Study: 27191923

Group type: EXPERIMENTAL
Intervention: Remifentanil (target concentration: young 3 ng/ml; old 2 ng/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Morphine (dose: young 0.1 mg/kg; old 0.07 mg/kg)
Number of subjects: 18
Study: 24183899

Group type: EXPERIMENTAL
Intervention: Ankle proprioceptive threshold (APrT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hip abduction rate of torque generation (RTG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Injured subjects
Number of subjects: 42